132 related articles for article (PubMed ID: 23294722)
21. Combined aberrant expression of Bmi1 and EZH2 is predictive of poor prognosis in glioma patients.
Wu Z; Wang Q; Wang L; Li G; Liu H; Fan F; Li Z; Li Y; Tu Y
J Neurol Sci; 2013 Dec; 335(1-2):191-6. PubMed ID: 24139839
[TBL] [Abstract][Full Text] [Related]
22. Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation.
Fujii S; Ito K; Ito Y; Ochiai A
J Biol Chem; 2008 Jun; 283(25):17324-32. PubMed ID: 18430739
[TBL] [Abstract][Full Text] [Related]
23. High level of EZH2 expression is linked to high density of CD8-positive T-lymphocytes and an aggressive phenotype in renal cell carcinoma.
Eichenauer T; Simmendinger L; Fraune C; Mandelkow T; Blessin NC; Kluth M; Hube-Magg C; Möller K; Clauditz T; Weidemann S; Dahlem R; Fisch M; Riechardt S; Simon R; Sauter G; Büscheck F; Rink M
World J Urol; 2021 Feb; 39(2):481-490. PubMed ID: 32303902
[TBL] [Abstract][Full Text] [Related]
24. WWOX protein expression varies among RCC histotypes and downregulation of WWOX protein correlates with less-favorable prognosis in clear RCC.
Lin JT; Tzai TS; Liao CY; Wang JS; Wu TT; Wang HY; Wu CH; Yu CC; Lu PJ
Ann Surg Oncol; 2013 Jan; 20(1):193-9. PubMed ID: 22555346
[TBL] [Abstract][Full Text] [Related]
25. MiR-138 induces renal carcinoma cell senescence by targeting EZH2 and is downregulated in human clear cell renal cell carcinoma.
Liang J; Zhang Y; Jiang G; Liu Z; Xiang W; Chen X; Chen Z; Zhao J
Oncol Res; 2013; 21(2):83-91. PubMed ID: 24406044
[TBL] [Abstract][Full Text] [Related]
26. Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines.
Jiang Y; Tong D; Lou G; Zhang Y; Geng J
Pathobiology; 2008; 75(4):244-51. PubMed ID: 18580070
[TBL] [Abstract][Full Text] [Related]
27. CD147 and VEGF expression in advanced renal cell carcinoma and their prognostic value.
Liang YX; He HC; Han ZD; Bi XC; Dai QS; Ye YK; Qin WJ; Zeng GH; Zhu G; Xu CL; Zhong WD
Cancer Invest; 2009 Aug; 27(7):788-93. PubMed ID: 19548138
[TBL] [Abstract][Full Text] [Related]
28. Significance of Fas expression alteration during tumor progression of renal cell carcinoma.
Sejima T; Miyagawa I
Int J Urol; 2006 Mar; 13(3):257-64. PubMed ID: 16643620
[TBL] [Abstract][Full Text] [Related]
29. [Expression of enhancer of zeste homolog 2 in esophageal squamous cell carcinoma and its prognostic value in postoperative patients].
Wang H; Wang M; Lian G; Wu D
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Jan; 33(1):99-102. PubMed ID: 23353165
[TBL] [Abstract][Full Text] [Related]
30. Polycomb group genes are targets of aberrant DNA methylation in renal cell carcinoma.
Avissar-Whiting M; Koestler DC; Houseman EA; Christensen BC; Kelsey KT; Marsit CJ
Epigenetics; 2011 Jun; 6(6):703-9. PubMed ID: 21610323
[TBL] [Abstract][Full Text] [Related]
31. Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma.
Wagener N; Macher-Goeppinger S; Pritsch M; Hüsing J; Hoppe-Seyler K; Schirmacher P; Pfitzenmaier J; Haferkamp A; Hoppe-Seyler F; Hohenfellner M
BMC Cancer; 2010 Oct; 10():524. PubMed ID: 20920340
[TBL] [Abstract][Full Text] [Related]
32. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
[TBL] [Abstract][Full Text] [Related]
33. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance.
Kikuchi J; Kinoshita I; Shimizu Y; Kikuchi E; Konishi J; Oizumi S; Kaga K; Matsuno Y; Nishimura M; Dosaka-Akita H
Cancer; 2010 Jun; 116(12):3015-24. PubMed ID: 20564407
[TBL] [Abstract][Full Text] [Related]
34. [Reappraisal of the impacts of human Runt-related transcription factor gene 3 expression on differentiation and prognosis of gastric cancer].
Wu BW; Zhang J; Fei XF; Zhu ZG; Cao WX
Zhonghua Wei Chang Wai Ke Za Zhi; 2007 Mar; 10(2):165-8. PubMed ID: 17380460
[TBL] [Abstract][Full Text] [Related]
35. The enhancer of zeste homolog 2 (EZH2), a potential therapeutic target, is regulated by miR-101 in renal cancer cells.
Sakurai T; Bilim VN; Ugolkov AV; Yuuki K; Tsukigi M; Motoyama T; Tomita Y
Biochem Biophys Res Commun; 2012 Jun; 422(4):607-14. PubMed ID: 22609199
[TBL] [Abstract][Full Text] [Related]
36. [Expression of P27kip1 in renal cell carcinoma and its clinical significance].
Wu P; Zheng SB
Nan Fang Yi Ke Da Xue Xue Bao; 2010 Aug; 30(8):1883-6, 1889. PubMed ID: 20813693
[TBL] [Abstract][Full Text] [Related]
37. Expression and significance of histone H3K27 demethylases in renal cell carcinoma.
Shen Y; Guo X; Wang Y; Qiu W; Chang Y; Zhang A; Duan X
BMC Cancer; 2012 Oct; 12():470. PubMed ID: 23057811
[TBL] [Abstract][Full Text] [Related]
38. EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients.
Rao ZY; Cai MY; Yang GF; He LR; Mai SJ; Hua WF; Liao YJ; Deng HX; Chen YC; Guan XY; Zeng YX; Kung HF; Xie D
Carcinogenesis; 2010 Sep; 31(9):1576-83. PubMed ID: 20668008
[TBL] [Abstract][Full Text] [Related]
39. Mechanism and function of decreased FOXO1 in renal cell carcinoma.
Zhou L; Yin B; Liu Y; Hong Y; Zhang C; Fan J
J Surg Oncol; 2012 Jun; 105(8):841-7. PubMed ID: 22213032
[TBL] [Abstract][Full Text] [Related]
40. Aberrant expression of EZH2 is associated with pathological findings and P53 alteration.
Shiogama S; Yoshiba S; Soga D; Motohashi H; Shintani S
Anticancer Res; 2013 Oct; 33(10):4309-17. PubMed ID: 24122997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
